drugset / Trial / NCT00793234

Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Knee Replacement Surgery

NCT00793234

RandomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and efficacy of a single administration of TB-402 for the prevention of VTE in patients undergoing knee replacement surgery.

Timeline

Start
2008-12
Primary completion
2010-01
Completion
2010-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Enoxaparin sodium Other / unclassified 40 mg Subcutaneous
Subject TB-402 Monoclonal antibody 0.3 mg/kg Intravenous
Subject TB-402 Monoclonal antibody 0.6 mg/kg Intravenous
Subject TB-402 Monoclonal antibody 1.2 mg/kg Intravenous

Indications

No indication recorded.